Is it Still Tough to Make Predictions About the Future?
نویسندگان
چکیده
منابع مشابه
It Is Tough to Make Predictions, Especially about the Future
Three lessons can be learned from this: first, there is a need for a less invasive and preferably reversible technique for lung volume reduction. Secondly, there is a need for prospective, randomized and (preferably sham) control of these techniques, and thirdly, there is a need for an a priori selection of patients, to predict the future. So, are there less invasive techniques out there? Inter...
متن کاملIt is tough to make predictions, especially about the future.
Three lessons can be learned from this: first, there is a need for a less invasive and preferably reversible technique for lung volume reduction. Secondly, there is a need for prospective, randomized and (preferably sham) control of these techniques, and thirdly, there is a need for an a priori selection of patients, to predict the future. So, are there less invasive techniques out there? Inter...
متن کاملIt Is Difficult to Make Predictions, Especially About the Future.
See related article, p XXX Physicists, politicians, poets, and punters understand the pitfalls of predicting the future. Similarly, predicting outcomes after stroke rehabilitation can be difficult when based on clinical impression, and several approaches to combining key variables in predictive models have been developed. In this issue, Scrutinio et al introduce a predictive model of functional...
متن کاملHow to make predictions about future infectious disease risks
Formal, quantitative approaches are now widely used to make predictions about the likelihood of an infectious disease outbreak, how the disease will spread, and how to control it. Several well-established methodologies are available, including risk factor analysis, risk modelling and dynamic modelling. Even so, predictive modelling is very much the 'art of the possible', which tends to drive re...
متن کاملPneumococcal conjugate vaccine for adults: "It's tough to make predictions, ...".
The 13-valent pneumococcal conjugate vaccine (PCV13) was licensed for adults in 2011. Data from the largest randomised controlled trial (RCT) on a pneumococcal vaccine published to date (the CAPITA study) show a vaccine efficacy of 45.6% for pneumonia caused by the 13 vaccine serotypes, including 45.0% for non-bacteraemic pneumonia [2]. Do these data justify the general use of PCV13 in adults? ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Transplantation
سال: 2019
ISSN: 0041-1337
DOI: 10.1097/tp.0000000000002839